Aljian Capital Management’s Novo Nordisk NVO Stock Holding History

Aljian Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$206K	Buy	+4,294	New	+$184K	0.04%	130
2026 Q1	–	Sell	-4,129	Closed	-$210K	–	133
2025 Q4	$210K	Sell	4,129 -1,250	-23%	-$63.9K	0.04%	117
2025 Q3	$298K	Buy	5,379 +538	+11%	+$31.5K	0.06%	107
2025 Q2	$334K	Buy	4,841 +20	+0.4%	+$1.36K	0.07%	99
2025 Q1	$335K	Buy	4,821 +30	+0.6%	+$2.48K	0.08%	100
2024 Q4	$412K	Buy	4,791 +330	+7%	+$35.7K	0.09%	84
2024 Q3	$531K	Buy	+4,461	New	+$595K	0.12%	76

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Aljian Capital Management's NVO Position: Q2 2026 in Review

Aljian Capital Management opened a new position in Novo Nordisk (NVO) in Q2 2026: 4,294 shares worth $206K. The stake represents 0.04% of the portfolio and ranks #130 among its holdings. This is a return to the name: Aljian Capital Management previously reported a position in NVO as recently as Q4 2025.

Aljian Capital Management first reported a position in NVO in Q3 2024 and has held it in 7 quarters since. The position peaked at $531K in Q3 2024. 1,354 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Aljian Capital Management held 4,294 shares of Novo Nordisk worth $206K as of Q2 2026.
Novo Nordisk was a new Aljian Capital Management position in Q2 2026.
Novo Nordisk made up 0.04% of Aljian Capital Management's portfolio in Q2 2026, its #130 holding.
Aljian Capital Management first reported a position in Novo Nordisk in Q3 2024 and has held it in 7 quarters since.
Aljian Capital Management's Novo Nordisk position peaked at $531K in Q3 2024.
1,354 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Aljian Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.